Dr Marcin Mankowski, Co-founder and Deputy Managing Partner of tranScrip, has been appointed tranScrip’s new Managing Partner.
Marcin has been integral to the success of the business over the last decade and is transitioning to the role at an exciting stage of the company’s growth. Underpinned by a recent significant minority investment from Palatine Private Equity Impact Fund, tranScrip is set to rapidly drive revenues with both organic growth and strategic acquisitions.
Marcin is a highly respected pharmaceutical physician with more than 25 years of big pharma, biotech and service sector managerial experience. He co-founded tranScrip in 2008 as a novel and innovative consultancy model, alongside the current Managing Partner, Dr Flic Gabbay, who is the President Elect of the Faculty of Pharmaceutical Medicine.
Together, they successfully built the organisation as a unique, global, leading life sciences consultancy which has generated over £55m of revenues from over 250 pharma and biotech companies to provide drug development, regulatory and post licensing support. Flic will continue to be actively involved in tranScrip as member of the Board, the Management Team and in supporting clients.
Marcin Mankowski commented: “I am taking over the leadership of the company with high hopes. We are expanding tranScrip’s geographical reach and further strengthening our expertise in therapy and functional areas to maintain our track record of success for our clients. With our unique team of in-house therapeutic area and operational experts, we are proud to support many research and development programmes which bring much needed medicines to patients. I would like to thank Flic for her dedication over the past years and I am very pleased that she will continue to support tranScrip and its clients.”
Flic Gabbay commented: "I am delighted that Marcin is taking over from me at this critical time in tranScrip’s growth. I am sure that under his leadership tranScrip will further grow and expand its successful track record of supporting early development activities and delivering products to the market for our clients. It’s an emotional time for me as I transition to be President of the Faculty of Pharmaceutical Medicine while stepping down from being the Managing Partner of tranScrip to become a more strategic and client facing Partner. I am really excited and look forward to continuing to support life sciences and the best interests of patients in both of these roles!”
tranScrip is a leading life sciences consultancy providing specialist support in the development and lifecycle of biopharmaceutical products to pharma and biotech companies.
We bring innovative solutions to clients’ global drug development needs. We deliver both strategic leadership and operational support, covering clinical, regulatory, drug safety and commercial from pre-clinical through to post-licensing.
tranScrip forms long-standing and successful partnerships with clients, a beneficial approach which maximises opportunities, reduces risk, creates value and accomplishes strategic goals, all for patient benefit. www.transcrip-partners.com